Association between metabolic score for insulin resistance and stroke: a nationally representative cross-sectional study from NHANES 2007–2018

Background: Stroke is a significant cerebrovascular disease and remains one of the leading causes of death and disability worldwide. Insulin resistance has been strongly linked to the incidence of stroke. Employing characteristics of metabolic syndrome, the Metabolic Score for Insulin Resistance (METS-IR) accurately measures insulin resistance. Nonetheless, the relationship between METS-IR and stroke risk is not well-established.

Methods: We analyzed data from the National Health and Nutrition Examination Survey (NHANES) covering the years 2007–2018. Participants providing complete METS-IR data and self-reported stroke information were included in the study. We utilized weighted multivariate regression to explore the relationship between METS-IR and stroke, performing subgroup analyses as well.

Results: A total of 14,794 participants were included, with an average METS-IR of 43.44 ± 12.68. The overall prevalence of self-reported stroke was 3.79%, with higher rates observed in upper METS-IR tertiles. An increase of one unit in METS-IR was associated with a 1% increase in stroke risk (OR = 1.01; 95% CI: 1.01–1.02). Interaction tests indicated no significant effects of gender, smoking status, alcohol consumption, hypertension, diabetes, physical activity, or serum cholesterol levels on this relationship. Notably, for participants younger than 60 years, the association was significantly stronger (OR = 1.02; 95% CI: 1.01–1.03), with a marked interaction (p = 0.0061).

Conclusion: Our findings indicate a positive correlation between higher METS-IR and increased stroke risk. Early intervention targeting insulin resistance may be a viable preventive measure against stroke, particularly in individuals under 60 years of age.

1 Introduction

Stroke, a devastating cerebrovascular disease, is the world’s second leading cause of death and ranks among the top three causes of death and disability combined (1, 2). Global research indicates that each year approximately 14 million individuals suffer their first stroke, with 6 million dying and another 26 million living with its effects (3). Over recent decades, the incidence, mortality, and disability rates of stroke have steadily increased, especially in low- and middle-income countries (3–5). The economic impact of stroke, including direct medical costs and indirect losses due to decreased labor (6). The estimated yearly economic impact of stroke is substantial. Annually, stroke accounts for more than $721 billion globally, equivalent to 0.66% of the world’s Gross Domestic Product (GDP), placing significant strain on individuals, families, and societies (3, 7). The American Heart Association cites several risk factors for stroke, such as smoking, alcohol consumption, hypertension, Type 2 diabetes, obesity, high cholesterol, and an unhealthy diet (8). The prevalence of metabolic syndrome, which is closely linked to high-sugar, high-fat diets, is increasing (9). Metabolic syndrome is associated with cardiovascular disease and stroke (10).

Metabolic syndrome (MetS) comprises four main components: insulin resistance (IR), atherogenic dyslipidemia, visceral adiposity, and endothelial dysfunction (11, 12). Bello-Chavolla et al. (13) introduced the Metabolic Score for Insulin Resistance (METS-IR), a novel index that evaluates insulin sensitivity using fasting plasma glucose (FPG), high-density lipoprotein cholesterol (HDL-C), fasting triglycerides (TG), and body mass index (BMI). METS-IR has shown higher diagnostic sensitivity and reliability for assessing insulin resistance compared to other indices like the triglyceride glucose index (TyG) and the homeostasis model assessment for insulin resistance (HOMA-IR) (14). Studies suggest that METS-IR provides a more precise prediction of insulin sensitivity, surpassed only by the euglycemic-hyperinsulinemic clamp (EHC), the gold standard for insulin resistance measurement (15). Moreover, METS-IR has been extensively validated in predicting metabolic conditions such as visceral adiposity and the incidence of Type 2 diabetes (13, 16, 17).

Recent studies have underscored the predictive value of METS-IR concerning cardiovascular outcomes, including stroke. For instance, METS-IR has been positively linked with the risk of cardiovascular events in patients with hypertension and obstructive sleep apnea, making it a potent marker for forecasting adverse outcomes (18). Additionally, another study found a strong association between elevated METS-IR levels and an increased risk of ischemic stroke, indicating that patients with higher METS-IR scores are more prone to ischemic strokes than those with lower scores (19). Furthermore, a Mendelian randomization study provided evidence supporting a causal link between METS-IR and the risk of ischemic stroke, particularly pointing to its relevance in the small artery occlusion subtype of stroke (20). These findings highlight the critical role of monitoring METS-IR as part of a comprehensive strategy for predicting and managing stroke risk and other cardiovascular conditions.

This study aims to examine the association between METS-IR and stroke risk using data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2018. We hypothesize that higher METS-IR levels correlate with an increased risk of stroke. By exploring this relationship, we aim to provide new insights into early interventions that could mitigate stroke risk by effectively managing insulin resistance.

2 Materials and methods

2.1 Sample selection

Data for this study were obtained from the National Health and Nutrition Examination Survey (NHANES), which utilizes a sophisticated multi-stage stratified probability sampling method to ensure a representative sample size (21). All NHANES research protocols received approval from the National Center for Health Statistics (NCHS) Research Ethics Review Board. Informed consent was obtained from all participants, or from parents and/or legal guardians for those under the age of 16.

For this study, we analyzed data from six NHANES cycles between 2007 and 2018. Initially, 59,842 participants were enrolled; however, 41,717 were excluded due to incomplete data on FPG, TG, HDL-C. An additional 323 participants were excluded because of incomplete data on BMI, and 3,098 were excluded due to unavailable stroke data. Ultimately, 14,794 participants were included in the study (Figure 1).

Figure 1

Figure 1. Participants screening flowchart.

2.2 METS-IR and stroke

The METS-IR index was employed as an exposure variable and was derived using the following formula: $\mathit{METS}-IR=ln\left[\left(2\times FPG+TG\right)\times BMI\right]÷ln\left(HDL-C\right)$ (13). After an 8.5-h fast, FPG and TG levels were measured with an automated biochemical analyzer. To calculate body mass index (BMI; kg/m²), we divided an individual’s weight (kg) by their height (m²).

Stroke was the outcome variable in this study. Based on the Medical Condition Questionnaire (MCQ) question no. 160f, individuals who answered “yes” were categorized as having had a stroke, while those who answered “no” were classified as non-stroke patients. The validity of self-reported strokes has been supported by previous studies (22, 23).

2.3 Covariates

In this study, covariates were selected based on prior research that identified risk factors associated with stroke (24, 25). These included age, gender, race, education levels, marital status, family poverty-to-income ratio, smoking status, alcohol consumption, hypertension, diabetes, physical activity levels, serum total cholesterol (mg/dL), and low-density lipoprotein cholesterol (LDL-C; mg/dL). Individuals were considered smokers if they had smoked at least 100 cigarettes in their lifetime. Alcohol consumption was defined by the question, “Had at least 12 alcoholic drinks in the past year.” Hypertension was determined if individuals self-reported the condition, used antihypertensive medication, or had a mean diastolic blood pressure ≥ 90 mmHg and/or a mean systolic blood pressure ≥ 140 mmHg. Diabetes criteria included the use of hypoglycemic medications, a diagnosis of diabetes, a 2-h plasma glucose level ≥ 200 mg/dL, a fasting plasma glucose level ≥ 126 mg/dL, or a hemoglobin A1c level ≥ 6.5%. Participants were categorized as engaging in vigorous physical activity if they participated in moderate-intensity sports for ≥10 min (26)(Wei et al., 2023).

2.4 Statistical methods

All statistical analyses adhered to the Centers for Disease Control and Prevention guidelines, considering complex multi-stage cluster surveys and using appropriate NHANES sample weights. Continuous variables are presented as means and standard deviations (SDs), while categorical variables are reported as proportions. Weighted Student’s t-tests were used for continuous data, and weighted Chi-Square tests were employed for categorical variables. To examine the characteristics of different METS-IR participants and their association with stroke incidence, METS-IR was categorized into tertiles. Multivariable logistic regression was used to explore the association between METS-IR and stroke incidence. Model 1 included no covariates. Model 2 was adjusted for gender, age, and race. Model 3, building on Model 2, also included adjustments for education level, marital status, family poverty-income ratio, smoking status, alcohol consumption, physical activity levels, serum cholesterol, and LDL cholesterol. Subgroup analyses were performed using stratified multivariable logistic regression models, stratifying by gender, age (<60 / ≥60 years), race, smoking status, alcohol consumption, hypertension, diabetes, physical activity levels, and serum cholesterol (<200 / ≥200 mg/dL). To manage the risk of Type I errors from multiple comparisons in subgroup analyses, we applied the false discovery rate (FDR) correction using the Benjamini-Hochberg procedure. This method was chosen to balance the control of false positives with the preservation of statistical power, particularly suitable for analyses involving multiple comparisons. Analyses were conducted using R version 4.1.3 and Empower software version 2.0. Statistical significance was set at a two-sided p-value <0.05.

3 Results

3.1 Baseline characteristics stratified by METS-IR tertiles

The present study included 14,794 participants, with an average age of 50.01 ± 17.61 years; 48.26% were male, and 51.74% were female. The prevalence of stroke among participants was 3.79%, increasing with each METS-IR tertile: 3.18% in tertile 1, 3.95% in tertile 2, and 4.24% in tertile 3 (p < 0.05). The mean METS-IR for participants was 43.44 ± 12.68, with ranges for tertiles 1, 2, and 3 of 17.14–36.75, 36.75–46.82, and 46.82–132.65, respectively. Significant differences were observed among the three METS-IR tertiles in terms of age, sex, race, education level, marital status, poverty-income ratio (PIR), smoking status, hypertension, diabetes, serum cholesterol, and LDL-C levels (all p < 0.05). Participants in the higher METS-IR tertiles tended to be male, married or living with a partner, smokers, have high blood pressure, not diagnosed with diabetes, and have higher LDL-C levels compared to those in the lower tertiles (all p < 0.05). No significant differences were found in alcohol consumption and physical activity levels (both p > 0.05). The baseline characteristics of the participants stratified by METS-IR tertiles are presented in Table 1.

Table 1

Table 1. Baseline characteristics of the study population according to METS-IR tertiles.

3.2 METS-IR and the incidence of stroke

We found that higher METS-IR was associated with an increased incidence of stroke. This association was statistically significant in Model 1 (OR = 1.01; 95% CI: 1.00–1.02; p = 0.0013) and Model 2 (OR = 1.01; 95% CI: 1.01–1.02; p < 0.0001), and it remained consistent in Model 3. Specifically, each unit increase in the METS-IR score was associated with a 1% higher risk of stroke (OR = 1.01; 95% CI: 1.01–1.02; p = 0.0006). For sensitivity analyses, we categorized METS-IR as a variable into three tertiles. The results showed that individuals in Tertile 3 had a 31% higher incidence of stroke compared to those in Tertile 1 (OR = 1.31; 95% CI: 1.04–1.63; p = 0.0192; Table 2).

Table 2

Table 2. Association between METS-IR and stroke.

A non-linear relationship was identified through smooth curve fitting (Figure 2). The solid red line represents the smooth curve fit between variables, while the blue bands illustrate the 95% confidence interval based on the fit. Additionally, we calculated the breakpoint to assess the quantitative relationship between METS-IR and stroke. However, the logarithmic likelihood ratio test yielded a p-value >0.05 (Table 3).

Figure 2

Figure 2. Non-linear associations between METS-IR and stroke.

Table 3

Table 3. Threshold effect analysis of METS-IR and stroke.

3.3 Subgroup analysis

To determine whether the positive association between METS-IR and stroke risk was consistent across various demographic factors, we conducted subgroup analyses and interaction tests stratified by sex, age, race, smoking status, alcohol consumption, hypertension, diabetes, physical activity levels, and serum cholesterol levels. Our results showed that the associations were consistent across all demographic factors, except for age, as illustrated in Figure 3 (all p for interaction >0.05). Notably, the association was significantly positive (OR = 1.02; 95% CI: 1.01–1.03; p < 0.0001) and more pronounced (p for interaction = 0.0061) among individuals under 60 years old.

Figure 3

Figure 3. Subgroup analysis of the effect of METS-IR on stroke.

4 Discussion

This study systematically analyzed the association between the Metabolic Score for Insulin Resistance (METS-IR) and stroke incidence in a large, representative sample of the U.S. population. We found a significant positive correlation between METS-IR and the risk of stroke, particularly in individuals under the age of 60. These results not only reinforce the sensitivity and reliability of METS-IR as an indicator of insulin resistance but also offer new insights for early stroke prevention strategies. Given the high prevalence of metabolic syndrome globally and the potential impact of insulin resistance on cerebrovascular health, these findings hold significant clinical relevance. They suggest that managing METS-IR-related parameters, such as fasting plasma glucose, triglycerides, BMI, and HDL-C levels, could effectively reduce the risk of stroke, especially in the context of an aging population and lifestyle changes.

To our knowledge, this is the first study to explore the association between METS-IR and stroke in an American population. METS-IR has been established as a reliable indicator of insulin resistance (13), which is implicated in various metabolism-related diseases such as diabetes (16, 17), visceral adiposity (13), and hyperuricemia (27). Recently, attention has focused on the relationship between METS-IR and cardiovascular disease (28–31). In South Korea, a cohort study involving 17,943 participants found an independent positive association between METS-IR and the prevalence of ischemic heart disease, with 1.9% of participants developing ischemic heart disease over 50 months of follow-up (29). It was also demonstrated that METS-IR, with an optimal threshold of 31.1, is a better predictor of ischemic heart disease than the diagnosis of metabolic syndrome alone (29). A cohort study from China investigated the predictive value of METS-IR for cardiovascular disease and its subtypes in patients with hypertension and obstructive sleep apnea, highlighting its clinical implications for early risk stratification (18). Additionally, it was reported that METS-IR was positively associated with blood pressure in participants with normal BMI, outperforming the TG/HDL-C ratio and TyG index, according to a large cross-sectional study from China (28). Qian et al. found that each quartile increase in METS-IR raised the risk of cardiovascular disease by 38% in middle-aged and elderly Chinese hypertensive patients over the age of 45, with LDL-C acting as a mediator (31). Cai et al. delved into the relationship between METS-IR and stroke within a Chinese population, discovering that higher METS-IR levels are associated with an increased risk of total and ischemic strokes, but not hemorrhagic strokes (19). Using data from previous NHANES cycles, Wang and his colleagues (30) reported a curvilinear relationship between METS-IR and subclinical myocardial injury, which was positively correlated with the incidence of subclinical myocardial injury when METS-IR exceeded the inflection point. More broadly, METS-IR has been extensively used to predict the occurrence (32), severity (32, 33), and prognosis (34) of coronary artery disease. Compared to other insulin resistance indices, including the TG/HDL-C ratio, TyG, and TyG-BMI, METS-IR showed the best predictive value (32, 33). Our results further explore the application of METS-IR in cardiovascular diseases. Elevated METS-IR levels were independently associated with an increased incidence of stroke in Americans, indicating that METS-IR could significantly influence stroke prevalence. Since METS-IR is a readily accessible, affordable, and accurate index, assessing it enables individuals to adopt early lifestyle changes and intervene in risk factors, thus potentially reducing disease incidence, particularly among those under the age of 60.

Neuroinflammation (35), oxidative stress (36), and hemodynamic disorders (37) may explain the link between metabolic syndrome and stroke. Metabolic syndrome is thought to induce a persistent low-grade inflammatory state (38). Chronically inflamed adipose tissue releases pro-inflammatory molecules, including interleukin-1 and tumor necrosis factor-alpha, contributing to systemic inflammation and oxidative stress (2, 39). This disrupts the balance between antioxidant defenses and reactive oxygen species, leading to damage to lipids, proteins, and DNA (40). Additionally, metabolic syndrome has been associated with impaired cerebrovascular reactivity (41). In individuals with metabolic syndrome, the carotid arteries—key suppliers of blood to the central nervous system—become stiffer and exhibit a thicker intima (42). In animal models of metabolic syndrome, researchers have observed brain damage resulting from astrocyte proliferation (43). Astrocytes play crucial roles in neuroinflammation, both protective and detrimental to the central nervous system (44). Their protective functions include maintaining blood–brain barrier integrity, reducing excitotoxicity, releasing neurotrophic factors, and supporting angiogenesis, axonal remodeling, and metabolic processes, all of which aid neurological recovery (44, 45). Additionally, astrocytes help regulate neuroinflammation to localize injury and facilitate vascular repair (46). However, they can also exacerbate neuroinflammation, release toxic factors, and form a glial scar that inhibits axonal regeneration, limiting functional recovery in the chronic phase of stroke (45, 47). Astrocytes may also contribute to excitotoxicity and brain edema by altering ion and neurotransmitter regulation (48). Chronic lipid overload and high glucose levels disrupt astrocyte function, leading to insulin resistance characterized by impaired insulin signaling, reduced glycogen synthesis, and altered gene expression (49). These metabolic disturbances enhance neurotoxicity and promote the secretion of inflammatory cytokines (50). Understanding the interactions between insulin resistance, astrocytic dysfunction, and neuroinflammation could clarify the mechanisms linking METS-IR to stroke, presenting a promising focus for future research.

IR is considered a fundamental cause of metabolic syndrome pathogenesis (11) and is commonly associated with obesity, particularly central or visceral obesity, as well as vascular dysfunction (51, 52). During IR, visceral adipocytes become a major source of circulating inflammatory factors, also known as adipokines (53). The resulting chronic inflammation, endothelial dysfunction, atherosclerosis, and hemodynamic changes are potential mechanisms linking IR to stroke. Chronic inflammation stimulates the pathogenic activity of macrophages and smooth muscle cells, leading to intracellular lipid accumulation and the formation of fatty streaks. These fatty streaks can develop into atherosclerotic lesions as the process progresses (54). In a healthy state, insulin promotes endothelial nitric oxide synthase, which produces nitric oxide, a potent vasodilator, through the PI3K/Akt signaling pathway. However, in the presence of insulin resistance, this pathway is disrupted, reducing nitric oxide production, and resulting in vasoconstriction and vascular endothelial dysfunction (55, 56). Atherosclerosis then develops from a series of pathological events initiated by localized endothelial dysfunction (54). Studies have also shown that insulin resistance enhances platelet activity, aggregation, and adhesion (57–59). These pathological changes alter hemodynamics and narrow the vascular lumen, leading to ischemia and changed tissue nutrient metabolism (60). Previous clinical studies have identified significantly impaired cerebral cortical perfusion in insulin-resistant patients compared to healthy individuals (61).

Conducted on an American population, our study is a large-scale cross-sectional analysis designed to explore the association between METS-IR and stroke. However, several limitations persist. Due to the inherent nature of cross-sectional studies, it is not possible to establish a causal relationship between METS-IR and stroke. Additionally, there is some bias because the outcome variables were collected via questionnaires rather than precise imaging techniques. Moreover, the questionnaire did not differentiate whether the stroke was ischemic or hemorrhagic, thus we were unable to define the association between METS-IR and each subtype of stroke. Furthermore, specific data to directly evaluate certain components of metabolic syndrome, such as visceral adiposity and endothelial dysfunction, were not available in the NHANES database. For example, measurements like abdominal fat assessed by MRI or endothelial function assessed by flow-mediated dilation tests could provide more accurate evaluations of these characteristics, but their absence limited our analysis. Despite these limitations, this cross-sectional study provides new insights into how METS-IR is associated with stroke.

5 Conclusion

A positive association between METS-IR and self-reported stroke was observed in an American population. Early intervention in insulin resistance could be an effective strategy for preventing stroke, especially in individuals under 60.

Data availability statement

Publicly available datasets were analyzed in this study. This data can be found at: https://www.cdc.gov/nchs/nhanes/?CDC_AAref_Val=https://www.cdc.gov/nchs/nhanes/index.htm.

Ethics statement

The studies involving humans were approved by National Center for Health Statistics (NCHS) Research Ethics Review Board. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.

Author contributions

LW: Data curation, Formal analysis, Writing – original draft, Writing – review & editing. YL: Writing – original draft, Writing – review & editing. HS: Writing – original draft, Writing – review & editing. JX: Writing – original draft, Writing – review & editing. XJ: Writing – original draft, Writing – review & editing.

Funding

The authors declare that financial support was received for the research, authorship, and/or publication of this article. XJ received support from the National Natural Science Foundation of China (grant number: 82474420), the Natural Science Foundation of Zhejiang Province (grant number: LY20H270010) and the Traditional Chinese Medicine Key Research Project of Zhejiang Province (grant number: 2022ZZ016).

Acknowledgments

We thank NHANES for providing the data necessary for this investigation.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Gorelick, PB. The global burden of stroke: persistent and disabling. Lancet Neurol. (2019) 18:417–8. doi: 10.1016/S1474-4422(19)30030-4

PubMed Abstract | Crossref Full Text | Google Scholar

2. Feigin, VL, Stark, BA, Johnson, CO, Roth, GA, Bisignano, C, Abady, GG, et al. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet Neurol. (2021) 20:795–820. doi: 10.1016/S1474-4422(21)00252-0

PubMed Abstract | Crossref Full Text | Google Scholar

3. Feigin, VL, Brainin, M, Norrving, B, Martins, S, Sacco, RL, Hacke, W, et al. World stroke organization (WSO): global stroke fact sheet 2022. Int J Stroke. (2022) 17:18–29. doi: 10.1177/17474930211065917

PubMed Abstract | Crossref Full Text | Google Scholar

4. O’Donnell, MJ, Chin, SL, Rangarajan, S, Xavier, D, Liu, L, Zhang, H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. (2016) 388:761–75. doi: 10.1016/S0140-6736(16)30506-2

PubMed Abstract | Crossref Full Text | Google Scholar

5. Lanas, F, and Seron, P. Facing the stroke burden worldwide. Lancet Glob Health. (2021) 9:e235–6. doi: 10.1016/S2214-109X(20)30520-9

PubMed Abstract | Crossref Full Text | Google Scholar

6. Mozaffarian, D, Benjamin, EJ, Go, AS, Arnett, DK, Blaha, MJ, Cushman, M, et al. Heart disease and stroke statistics—2015 update: A report from the American Heart Association. Circulation. (2015) 131:e29–e322. doi: 10.1161/CIR.0000000000000152

PubMed Abstract | Crossref Full Text | Google Scholar

7. Brainin, M, Feigin, VL, Norrving, B, Martins, SCO, Hankey, GJ, and Hachinski, VS. Global prevention of stroke and dementia: the WSO declaration. Lancet Neurol. (2020) 19:487–8. doi: 10.1016/S1474-4422(20)30141-1

PubMed Abstract | Crossref Full Text | Google Scholar

8. Martin, SS, Aday, AW, Almarzooq, ZI, Anderson, CAM, Arora, P, Avery, CL, et al. Heart disease and stroke statistics: A report of US and global data from the American Heart Association. Circulation. (2024) 149:e347–913. doi: 10.1161/CIR.0000000000001209

PubMed Abstract | Crossref Full Text | Google Scholar

9. Saklayen, MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. (2018) 20:12. doi: 10.1007/s11906-018-0812-z

PubMed Abstract | Crossref Full Text | Google Scholar

10. Alkhulaifi, F, and Darkoh, C. Meal timing, meal frequency and metabolic syndrome. Nutrients. (2022) 14:1719. doi: 10.3390/nu14091719

PubMed Abstract | Crossref Full Text | Google Scholar

11. Huang, PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. (2009) 2:231–7. doi: 10.1242/dmm.001180

PubMed Abstract | Crossref Full Text | Google Scholar

12. Lemieux, I, and Després, J-P. Metabolic syndrome: past, present and future. Nutrients. (2020) 12:3501. doi: 10.3390/nu12113501

PubMed Abstract | Crossref Full Text | Google Scholar

13. Bello-Chavolla, OY, Almeda-Valdes, P, Gomez-Velasco, D, Viveros-Ruiz, T, Cruz-Bautista, I, Romo-Romo, A, et al. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. (2018) 178:533–44. doi: 10.1530/EJE-17-0883

PubMed Abstract | Crossref Full Text | Google Scholar

14. Tunç, KS. Insulin resistance in non-diabetic hypothyroid patients: a critical examination of METS-IR as a diagnostic marker. Curr Med Res Opin. (2023) 39:1431–7. doi: 10.1080/03007995.2023.2270422

PubMed Abstract | Crossref Full Text | Google Scholar

15. Sheng, G, Kuang, M, Yang, R, Zhong, Y, Zhang, S, and Zou, Y. Evaluation of the value of conventional and unconventional lipid parameters for predicting the risk of diabetes in a non-diabetic population. J Transl Med. (2022) 20:266. doi: 10.1186/s12967-022-03470-z

PubMed Abstract | Crossref Full Text | Google Scholar

16. Cai, X-T, Zhu, Q, Liu, S-S, Wang, M-R, Wu, T, Hong, J, et al. Associations between the metabolic score for insulin resistance index and the risk of type 2 diabetes mellitus among non-obese adults: insights from a population-based cohort study. Int J Gen Med. (2021) 14:7729–40. doi: 10.2147/IJGM.S336990

PubMed Abstract | Crossref Full Text | Google Scholar

17. Wang, Z, Xie, J, Wang, J, Feng, W, Liu, N, and Liu, Y. Association between a novel metabolic score for insulin resistance and mortality in people with diabetes. Front Cardiovasc Med. (2022) 9:895609. doi: 10.3389/fcvm.2022.895609

PubMed Abstract | Crossref Full Text | Google Scholar

18. Yang, W, Cai, X, Hu, J, Wen, W, Mulalibieke, H, Yao, X, et al. The metabolic score for insulin resistance (METS-IR) predicts cardiovascular disease and its subtypes in patients with hypertension and obstructive sleep apnea. Clin Epidemiol. (2023) 15:177–89. doi: 10.2147/CLEP.S395938

PubMed Abstract | Crossref Full Text | Google Scholar

19. Cai, X, Hu, J, Zhu, Q, Wang, M, Liu, S, Dang, Y, et al. Relationship of the metabolic score for insulin resistance and the risk of stroke in patients with hypertension: A cohort study. Front Endocrinol. (2022) 13:1049211. doi: 10.3389/fendo.2022.1049211

PubMed Abstract | Crossref Full Text | Google Scholar

20. Chen, W, Wang, S, Lv, W, and Pan, Y. Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis. BMJ Open Diabetes Res Care. (2020) 8:e001217. doi: 10.1136/bmjdrc-2020-001217

PubMed Abstract | Crossref Full Text | Google Scholar

21. Curtin, LR, Mohadjer, LK, Dohrmann, SM, Kruszon-Moran, D, Mirel, LB, Carroll, MD, et al. National Health and nutrition examination survey: sample design, 2007-2010. Vital Health Stat. (2013) 2:1–23.

Google Scholar

22. Wang, Y, Yang, L, Zhang, Y, and Liu, J. Relationship between circadian syndrome and stroke: A cross-sectional study of the national health and nutrition examination survey. Front Neurol. (2022) 13:946172. doi: 10.3389/fneur.2022.946172

PubMed Abstract | Crossref Full Text | Google Scholar

23. Ye, J, Hu, Y, Chen, X, Yin, Z, Yuan, X, Huang, L, et al. Association between the weight-adjusted waist index and stroke: a cross-sectional study. BMC Public Health. (2023) 23:1689. doi: 10.1186/s12889-023-16621-8

PubMed Abstract | Crossref Full Text | Google Scholar

24. Li, X, Zhang, R, and Xu, J. Association between physical activity and stroke in patients with cardiovascular risk factors: findings from NHANES 2007–2020. Asian J Surg. (2024) doi: 10.1016/j.asjsur.2024.10.057 (in press).

Crossref Full Text | Google Scholar

25. Mao, Y, Weng, J, Xie, Q, Wu, L, Xuan, Y, Zhang, J, et al. Association between dietary inflammatory index and stroke in the US population: evidence from NHANES 1999–2018. BMC Public Health. (2024) 24:50. doi: 10.1186/s12889-023-17556-w

PubMed Abstract | Crossref Full Text | Google Scholar

26. Wei, B, Dong, Q, Ma, J, and Zhang, A. The association between triglyceride-glucose index and cognitive function in nondiabetic elderly: NHANES 2011-2014. Lipids Health Dis. (2023) 22:188. doi: 10.1186/s12944-023-01959-0

PubMed Abstract | Crossref Full Text | Google Scholar

27. Wang, H, Zhang, J, Pu, Y, Qin, S, Liu, H, Tian, Y, et al. Comparison of different insulin resistance surrogates to predict hyperuricemia among U.S. non-diabetic adults. Front Endocrinol. (2022) 13:1028167. doi: 10.3389/fendo.2022.1028167

PubMed Abstract | Crossref Full Text | Google Scholar

28. Liu, XZ, Fan, J, and Pan, SJ. METS-IR, a novel simple insulin resistance indexes, is associated with hypertension in normal-weight Chinese adults. J Clin Hypertens. (2019) 21:1075–81. doi: 10.1111/jch.13591

PubMed Abstract | Crossref Full Text | Google Scholar

29. Yoon, J, Jung, D, Lee, Y, and Park, B. The metabolic score for insulin resistance (METS-IR) as a predictor of incident ischemic heart disease: A longitudinal study among Korean without diabetes. J Pers Med. (2021) 11:742. doi: 10.3390/jpm11080742

PubMed Abstract | Crossref Full Text | Google Scholar

30. Wang, Z, Li, W, Li, J, and Liu, N. The nonlinear correlation between a novel metabolic score for insulin resistance and subclinical myocardial injury in the general population. Front Endocrinol. (2022) 13:889379. doi: 10.3389/fendo.2022.889379

PubMed Abstract | Crossref Full Text | Google Scholar

31. Qian, T, Sheng, X, Shen, P, Fang, Y, Deng, Y, and Zou, G. Mets-IR as a predictor of cardiovascular events in the middle-aged and elderly population and mediator role of blood lipids. Front Endocrinol. (2023) 14:1224967. doi: 10.3389/fendo.2023.1224967

PubMed Abstract | Crossref Full Text | Google Scholar

32. Wu, Z, Cui, H, Li, W, Zhang, Y, Liu, L, Liu, Z, et al. Comparison of three non-insulin-based insulin resistance indexes in predicting the presence and severity of coronary artery disease. Front Cardiovasc Med. (2022) 9:918359. doi: 10.3389/fcvm.2022.918359

PubMed Abstract | Crossref Full Text | Google Scholar

33. Zhang, Y, Wang, R, Fu, X, and Song, H. Non-insulin-based insulin resistance indexes in predicting severity for coronary artery disease. Diabetol Metab Syndr. (2022) 14:191. doi: 10.1186/s13098-022-00967-x

PubMed Abstract | Crossref Full Text | Google Scholar

34. Guo, D, Zhang, C, Zhang, M, Wu, Z, Liu, X, Zhang, Y, et al. Metabolic score for insulin resistance predicts major adverse cardiovascular event in premature coronary artery disease. Aging. (2024) 16:6364–83. doi: 10.18632/aging.205710

PubMed Abstract | Crossref Full Text | Google Scholar

35. Chen, H, He, Y, Chen, S, Qi, S, and Shen, J. Therapeutic targets of oxidative/nitrosative stress and neuroinflammation in ischemic stroke: applications for natural product efficacy with omics and systemic biology. Pharmacol Res. (2020) 158:104877. doi: 10.1016/j.phrs.2020.104877

PubMed Abstract | Crossref Full Text | Google Scholar

36. Zhou, X, Chen, H, Wang, L, Lenahan, C, Lian, L, Ou, Y, et al. Mitochondrial dynamics: A potential therapeutic target for ischemic stroke. Front Aging Neurosci. (2021) 13:721428. doi: 10.3389/fnagi.2021.721428

PubMed Abstract | Crossref Full Text | Google Scholar

37. Beijers, HJBH, Henry, RMA, Bravenboer, B, Ferreira, I, Dekker, JM, Nijpels, G, et al. Metabolic syndrome in nondiabetic individuals associated with maladaptive carotid remodeling: the Hoorn study. Am J Hypertens. (2011) 24:429–36. doi: 10.1038/ajh.2010.256

PubMed Abstract | Crossref Full Text | Google Scholar

38. Silveira Rossi, JL, Barbalho, SM, Reverete De Araujo, R, Bechara, MD, Sloan, KP, and Sloan, LA. Metabolic syndrome and cardiovascular diseases: going beyond traditional risk factors. Diabetes Metab Res Rev. (2022) 38:e3502. doi: 10.1002/dmrr.3502

PubMed Abstract | Crossref Full Text | Google Scholar

39. Lehrskov, LL, and Christensen, RH. The role of interleukin-6 in glucose homeostasis and lipid metabolism. Semin Immunopathol. (2019) 41:491–9. doi: 10.1007/s00281-019-00747-2

PubMed Abstract | Crossref Full Text | Google Scholar

40. Sharifi-Rad, M, Anil Kumar, NV, Zucca, P, Varoni, EM, Dini, L, Panzarini, E, et al. Lifestyle, oxidative stress, and antioxidants: Back and forth in the pathophysiology of chronic diseases. Front Physiol. (2020) 11:694. doi: 10.3389/fphys.2020.00694

PubMed Abstract | Crossref Full Text | Google Scholar

41. Giannopoulos, S, Boden-Albala, B, Choi, JH, Carrera, E, Doyle, M, Perez, T, et al. Metabolic syndrome and cerebral vasomotor reactivity. Eur J Neurol. (2010) 17:1457–62. doi: 10.1111/j.1468-1331.2010.03087.x

PubMed Abstract | Crossref Full Text | Google Scholar

42. Sipilä, K, Moilanen, L, Nieminen, T, Reunanen, A, Jula, A, Salomaa, V, et al. Metabolic syndrome and carotid intima media thickness in the health 2000 survey. Atherosclerosis. (2009) 204:276–81. doi: 10.1016/j.atherosclerosis.2008.08.029

PubMed Abstract | Crossref Full Text | Google Scholar

43. Tomassoni, D, Nwankwo, IE, Gabrielli, MG, Bhatt, S, Muhammad, AB, Lokhandwala, MF, et al. Astrogliosis in the brain of obese Zucker rat: A model of metabolic syndrome. Neurosci Lett. (2013) 543:136–41. doi: 10.1016/j.neulet.2013.03.025

PubMed Abstract | Crossref Full Text | Google Scholar

44. Shen, X-Y, Gao, Z-K, Han, Y, Yuan, M, Guo, Y-S, and Bi, X. Activation and role of astrocytes in ischemic stroke. Front Cell Neurosci. (2021) 15:755955. doi: 10.3389/fncel.2021.755955

PubMed Abstract | Crossref Full Text | Google Scholar

45. Li, L, Zhou, J, Han, L, Wu, X, Shi, Y, Cui, W, et al. The specific role of reactive astrocytes in stroke. Front Cell Neurosci. (2022) 16:850866. doi: 10.3389/fncel.2022.850866

PubMed Abstract | Crossref Full Text | Google Scholar

46. Williamson, MR, Fuertes, CJA, Dunn, AK, Drew, MR, and Jones, TA. Reactive astrocytes facilitate vascular repair and remodeling after stroke. Cell Rep. (2021) 35:109048. doi: 10.1016/j.celrep.2021.109048

PubMed Abstract | Crossref Full Text | Google Scholar

47. Liu, Z, and Chopp, M. Astrocytes, therapeutic targets for neuroprotection and neurorestoration in ischemic stroke. Prog Neurobiol. (2016) 144:103–20. doi: 10.1016/j.pneurobio.2015.09.008

PubMed Abstract | Crossref Full Text | Google Scholar

48. Dronne, M-A, Grenier, E, Dumont, T, Hommel, M, and Boissel, J-P. Role of astrocytes in grey matter during stroke: A modelling approach. Brain Res. (2007) 1138:231–42. doi: 10.1016/j.brainres.2006.12.062

PubMed Abstract | Crossref Full Text | Google Scholar

49. Heni, M, Eckstein, SS, Schittenhelm, J, Böhm, A, Hogrefe, N, Irmler, M, et al. Ectopic fat accumulation in human astrocytes impairs insulin action. R Soc Open Sci. (2020) 7:200701. doi: 10.1098/rsos.200701

PubMed Abstract | Crossref Full Text | Google Scholar

50. Bahniwal, M, Little, JP, and Klegeris, A. High glucose enhances neurotoxicity and inflammatory cytokine secretion by stimulated human astrocytes. Curr Alzheimer Res. (2017) 14:731–41. doi: 10.2174/1567205014666170117104053

PubMed Abstract | Crossref Full Text | Google Scholar

51. Gluvic, Z, Zaric, B, Resanovic, I, Obradovic, M, Mitrovic, A, Radak, D, et al. Link between metabolic syndrome and insulin resistance. Curr Vasc Pharmacol. (2016) 15:30–9. doi: 10.2174/1570161114666161007164510

PubMed Abstract | Crossref Full Text | Google Scholar

52. Hill, MA, Yang, Y, Zhang, L, Sun, Z, Jia, G, Parrish, AR, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. (2021) 119:154766. doi: 10.1016/j.metabol.2021.154766

PubMed Abstract | Crossref Full Text | Google Scholar

53. Haidara, M, Dobutovic, B, Soskic, S, and Rizzo, M. Evaluation of the possible contribution of antioxidants Administration in Metabolic Syndrome. Curr Pharm Des. (2011) 17:3699–712. doi: 10.2174/138161211798220882

PubMed Abstract | Crossref Full Text | Google Scholar

54. Poznyak, A, Grechko, AV, Poggio, P, Myasoedova, VA, Alfieri, V, and Orekhov, AN. The diabetes mellitus–atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. (2020) 21:1835. doi: 10.3390/ijms21051835

Crossref Full Text | Google Scholar

55. Beckman, JA, Goldfine, AB, Dunaif, A, Gerhard-Herman, M, and Creager, MA. Endothelial function varies according to insulin resistance disease type. Diabetes Care. (2007) 30:1226–32. doi: 10.2337/dc06-2142

PubMed Abstract | Crossref Full Text | Google Scholar

56. Bakker, W, Eringa, EC, Sipkema, P, and Van Hinsbergh, VWM. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res. (2009) 335:165–89. doi: 10.1007/s00441-008-0685-6

PubMed Abstract | Crossref Full Text | Google Scholar

57. Randriamboavonjy, V, and Fleming, I. Insulin, insulin resistance, and platelet signaling in diabetes. Diabetes Care. (2009) 32:528–30. doi: 10.2337/dc08-1942

PubMed Abstract | Crossref Full Text | Google Scholar

58. Santilli, F, Vazzana, N, Liani, R, Guagnano, MT, and Davì, G. Platelet activation in obesity and metabolic syndrome. Obes Rev. (2012) 13:27–42. doi: 10.1111/j.1467-789X.2011.00930.x

PubMed Abstract | Crossref Full Text | Google Scholar

59. Moore, SF, Williams, CM, Brown, E, Blair, TA, Harper, MT, Coward, RJ, et al. Loss of the insulin receptor in murine megakaryocytes/platelets causes thrombocytosis and alterations in IGF signalling. Cardiovasc Res. (2015) 107:9–19. doi: 10.1093/cvr/cvv132

PubMed Abstract | Crossref Full Text | Google Scholar

60. Martínez, MS, García, A, Luzardo, E, Chávez-Castillo, M, Olivar, LC, Salazar, J, et al. Energetic metabolism in cardiomyocytes: molecular basis of heart ischemia and arrhythmogenesis. Vessel Plus. (2017) 1:130–141. doi: 10.20517/2574-1209.2017.34

Crossref Full Text | Google Scholar

61. Rusinek, H, Ha, J, Yau, PL, Storey, P, Tirsi, A, Tsui, WH, et al. Cerebral perfusion in insulin resistance and type 2 diabetes. J Cereb Blood Flow Metab. (2015) 35:95–102. doi: 10.1038/jcbfm.2014.173

PubMed Abstract | Crossref Full Text | Google Scholar